Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease
In December, 2021 at the IXth All-Russian Congress «Pulmonary Hypertension 2021» the first Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart disease in adults were approved. The expert group discussed many contentious issues, including the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2022-10-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/6339 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849693630104600576 |
|---|---|
| author | A. A. Shmalts S. V. Gorbachevsky T. V. Martynyuk S. N. Nakonechnikov |
| author_facet | A. A. Shmalts S. V. Gorbachevsky T. V. Martynyuk S. N. Nakonechnikov |
| author_sort | A. A. Shmalts |
| collection | DOAJ |
| description | In December, 2021 at the IXth All-Russian Congress «Pulmonary Hypertension 2021» the first Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart disease in adults were approved. The expert group discussed many contentious issues, including the need for diagnostic tests for vasoreactivity. Invasive registration of the reaction of the pulmonary vessels to vasodilators – a vasoreactivity testing – in idiopathic, hereditary and drug- and toxin-induced pulmonary arterial hypertension (PAH) is used to determine indications for calcium antagonist therapy, in PAH associated with uncorrected congenital heart disease (CHD) in children – to determine the indications for surgical treatment. The use of a vasoreactivity testing to assess the operability of adult patients with congenital heart disease is inappropriate. An overview of the performance technique, specific pulmonary vasodilators and criteria for evaluating the test for vasoreactivity in various subgroups of PH associated with CHD is given. |
| format | Article |
| id | doaj-art-90aeca79c83a4ae5a6d4983cef7fd582 |
| institution | DOAJ |
| issn | 2225-1685 2305-0748 |
| language | Russian |
| publishDate | 2022-10-01 |
| publisher | InterMedservice |
| record_format | Article |
| series | Евразийский Кардиологический Журнал |
| spelling | doaj-art-90aeca79c83a4ae5a6d4983cef7fd5822025-08-20T03:20:20ZrusInterMedserviceЕвразийский Кардиологический Журнал2225-16852305-07482022-10-0103586410.38109/2225-1685-2022-3-58-646275Vasoreactivity testing in pulmonary hypertension associated with congenital heart diseaseA. A. Shmalts0S. V. Gorbachevsky1T. V. Martynyuk2S. N. Nakonechnikov3A. N. Bakulev Scientific Center for Cardiovascular Surgery; Ministry of the Russian FederationA. N. Bakulev Scientific Center for Cardiovascular Surgery; Ministry of the Russian FederationE. I. Chazov National Medical Research Center of Cardiology; N. I. Pirogov Russian Medical Research Medical UniversityN. I. Pirogov Russian Medical Research Medical University, Russian Medical Society for Arterial HypertensionIn December, 2021 at the IXth All-Russian Congress «Pulmonary Hypertension 2021» the first Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart disease in adults were approved. The expert group discussed many contentious issues, including the need for diagnostic tests for vasoreactivity. Invasive registration of the reaction of the pulmonary vessels to vasodilators – a vasoreactivity testing – in idiopathic, hereditary and drug- and toxin-induced pulmonary arterial hypertension (PAH) is used to determine indications for calcium antagonist therapy, in PAH associated with uncorrected congenital heart disease (CHD) in children – to determine the indications for surgical treatment. The use of a vasoreactivity testing to assess the operability of adult patients with congenital heart disease is inappropriate. An overview of the performance technique, specific pulmonary vasodilators and criteria for evaluating the test for vasoreactivity in various subgroups of PH associated with CHD is given.https://www.heartj.asia/jour/article/view/6339pulmonary hypertensionpulmonary arterial hypertensioncongenital heart diseasevasoreactivity test |
| spellingShingle | A. A. Shmalts S. V. Gorbachevsky T. V. Martynyuk S. N. Nakonechnikov Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease Евразийский Кардиологический Журнал pulmonary hypertension pulmonary arterial hypertension congenital heart disease vasoreactivity test |
| title | Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease |
| title_full | Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease |
| title_fullStr | Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease |
| title_full_unstemmed | Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease |
| title_short | Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease |
| title_sort | vasoreactivity testing in pulmonary hypertension associated with congenital heart disease |
| topic | pulmonary hypertension pulmonary arterial hypertension congenital heart disease vasoreactivity test |
| url | https://www.heartj.asia/jour/article/view/6339 |
| work_keys_str_mv | AT aashmalts vasoreactivitytestinginpulmonaryhypertensionassociatedwithcongenitalheartdisease AT svgorbachevsky vasoreactivitytestinginpulmonaryhypertensionassociatedwithcongenitalheartdisease AT tvmartynyuk vasoreactivitytestinginpulmonaryhypertensionassociatedwithcongenitalheartdisease AT snnakonechnikov vasoreactivitytestinginpulmonaryhypertensionassociatedwithcongenitalheartdisease |